IMMIX BIOPHARMA, INC. Debt Securities, Available-for-sale, Realized Gain
IMMIX BIOPHARMA, INC. (IMMX) reported Debt Securities, Available-for-sale, Realized Gain of $49.33 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. debt securities, available-for-sale, realized gain for the quarter ending 2026-06-30 was $38.68K.
- IMMIX BIOPHARMA, INC. debt securities, available-for-sale, realized gain for the quarter ending 2026-03-31 was $10.65K.
| Period end | Debt Securities, Available-for-sale, Realized Gain 3 month | Debt Securities, Available-for-sale, Realized Gain 6 month |
|---|---|---|
| 2026-06-30 | $38.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $49.33K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $10.65K 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |